Fludarabine, Thiotepa, ATG, and TBI conditioning regimen

The combination of fludarabine, thiotepa, antithymocyte globulin (ATG), and total body irradiation (TBI) is a conditioning regimen used primarily in hematopoietic stem cell transplantation, particularly for patients receiving cord blood transplants or other allogeneic transplants. This regimen combines several components that work together to prepare the recipient's body for transplantation: 1. **Fludarabine**: A purine nucleoside analog that inhibits DNA synthesis and has potent immunosuppressive properties[1][2]. 2. **Thiotepa**: An alkylating agent that causes DNA cross-linking and has both immunosuppressive and antineoplastic effects[2]. 3. **Antithymocyte Globulin (ATG)**: An immunoglobulin that targets T-cells, causing T-cell depletion through complement-mediated cytotoxicity or apoptosis[6][9][10]. 4. **Total Body Irradiation (TBI)**: Radiation therapy administered to the entire body that suppresses the immune system and helps prevent graft rejection[3][5][7]. This conditioning regimen is classified as either myeloablative or non-myeloablative/reduced-intensity depending on the dosages used, particularly of TBI. The regimen is typically administered before transplantation to: - Suppress the recipient's immune system to prevent rejection of donor cells - Create space in the bone marrow for donor stem cells - Eradicate residual malignant cells (in cases of hematologic malignancies) The specific dosing varies by protocol, but typically includes: - Fludarabine: 30 mg/m² daily for 4-6 days - Thiotepa: Approximately 10 mg/kg - ATG: Variable dosing, often 1.25-3.75 mg/kg over 2-4 days - TBI: From 200 cGy (non-myeloablative) to 1200-1320 cGy (myeloablative)[1][2][5][7] This combination has shown efficacy in achieving donor engraftment rates above 80% in some studies[1]. It's primarily used in patients with hematologic malignancies undergoing cord blood transplantation or other forms of allogeneic stem cell transplantation.

Other names

FTAI regimenFludarabine/Thiotepa/ATG/TBI regimen